Personalized medicine and cancer

Journal of Personalized Medicine

Volumn 2, Issue 1, 2012, Pages

  Verma, Mukesh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Diagnosis; Epigenome; Genome; Metabolome; Outcome; Personalized medicine; Proteome; Survival; Treatment

Indexed keywords

CRIZOTINIB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; PROTEOME; TAMOXIFEN;

BREAST CANCER; CANCER SPECIFIC SURVIVAL; CLINICAL TRIAL (TOPIC); COLON CANCER; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HEALTH CARE; HUMAN; LUNG CANCER; LYMPHOMA; METABOLOME; MYELOID LEUKEMIA; NEOPLASM; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROSTATE CANCER; REVIEW; RISK FACTOR; SURVIVAL; SYSTEMATIC REVIEW (TOPIC);

EID: 85041166555     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm2010001     Document Type: Review

References (50)

1. Stricker, T.; Catenacci, D.V.; Siewert, S.Y. Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin. Oncol. 2011, 38, 173-185.
2. Schroth, W.; Goetz, M.P.; Hamann, U.; Fasching, P.A.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V.J.; Ames, M.M.; Safgren, S.L.; Kuffel, M.J.; Ulmer, H.U.; Boländer, J.; Strick, R.; Beckmann, M.W.; Koelbl, H; Weinshilboum, R.M.; Ingle, J.N.; Eichelbaum, M.; Schwab, M.; Brauch, H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302, 1429-1436.
3. Offit, K. Personalized medicine: new genomics, old lessons. Hum. Genet. 2011, 130, 3-14.
4. Baehner, F.L.; Lee, M.; Demeure, M.J.; Bussey, K.J.; Kiefer, J.A.; Barrett, M.T. Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J. Surg. Oncol. 2011, 103, 563-573.
5. Song, M.; Lee, K.M.; Kang, D. Breast cancer prevention based on gene-environment interaction. Mol. Carcinog. 2011, 50, 280-290.
6. de Souza, J.A.; Olopade, O.I. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin. Oncol. 2011, 38, 263-273.
7. Brauch, H.; Murdter, T.E.; Eichelbaum, M.; Schwab, B. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 2009, 55, 1770-1782.
8. Brauch, H.; Jordan, V.C. Targeting of tamoxifen antitumor action for the treatment and prevention of breast cancer: the "personalized approach. " Eur. J. Cancer. 2009, 45, 2274-2283.
9. Hoskins, J.M.; Carey, L.A.; McLeod, H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 2009, 9, 576-586.
10. Schroth, W.; Hammen, U.; Fasching, A.P.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H. CYP2D6 polymorphism as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res. 2010, 16, 4468-4477.
11. Hatzis, C.; Pusztai, L.; Valero, V.; Booser, D.J.; Esserman, L.; Lluch, A.; Vidaurre, T.; Holmes, F.; Souchon, E.; Wang, H.; Martin M.; et al. A genomic predictor of response and survival following taxane-anthracyclin chemotherapy for invasive breast cancer. JAMA 2011, 305, 1873-1881.
12. Arao, T.; Matsumoto, K.; Maegawa, M.; Nishio, K. What can and cannot be done using a microarray analysis? Traetment stratification and clinical applications in oncology. Biol. Pharm. Bull. 2011, 34, 1789-1793.
13. Fernandez, O.A.; Jolis, L.L.; Vinas, V.G. Individualization of treatment strategies. Adv. Therp. 2011, 6, 19-38.
14. Barginear, M.F.; Jaremko, M.; Peter, I.; Yu, C.; Kasai, Y.; Kemeny, M.; Raptis, G.; Desnick, R.J. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect of and active metabolite isomers and the antiestrogenic activity score. Clin. Pharmacol. Ther. 2011, 90, 605-611.
15. Conin-Fenton, D.P.; Lash, T.L. Clinical epidemiology and pharmacology of CYp2D6 inhibition related to breast cancer outcomes. Expert Rev. Clin. Pharmacol. 2011, 4, 363-377.
16. Fleeman, N.; Martin, S.C.; Payne, K.; Boland, A.; Dickson, R.; Dundar, Y.; Fernández Santander, A.; Howell, S.; Newman, W.; Oyee, J.; Walley, T. The clinical effectiveness and costeffectiveness of genotyping for CYP2D6 for the management of women with breast cancer with tamoxifen: a systematic review. Health Technol. Assess. 2011, 15, 1-102.
17. Lu, W.J.; Xu, C.; Pei, Z.; Mayhoub, A.S.; Cushman, M.; Flockhart, D.A. The temoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res. Treat. 2011, in press.
18. Krigsman, O.; Ropeman, P.; Zwart, W. Carroll, J.S.; Tian, S.; de Snoo, F.A.; Bender, R.A.; Bernards, R.; Glas, A.M. A diagnostic gene profile for molecular subtyping of breat cancer associated with treatment response. Breast Cancer Res. Treat. 2011, PMID 21814749 in press.
19. Rutgers, E.; Pictaart-Gebhart, M. J; Bogaerts, J.; Delaloge, S.; Veer, L.V.; Rubio, I.T.; Viale, G.; Thompson, A.M.; Passalacqua, R.; Nitz, U.; Vindevoghel, A.; Pierga, J.Y.; Ravdin, P.M.; Werutsky, G.; Cardoso, F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur. J. Cancer 2011, 47, 2742-2749.
20. Kim, C.; Tang, G.; Pogue-Geile, K.L.; Costantino, J.P.; Baehner, F.L.; Baker, J.; Cronin, M.T.; Watson, D.; Shak, S.; Bohn, O.L.; Fumagalli, D.; et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen-receptorpositive breast cancer. J. Clin. Oncol. 2011, 29, 4160-4167.
21. Catenacci, D.V.; Kozloff, M.; Kindler, H.L.; Polite, B. Personalized colon cancer care in 2010. Semin. Oncol. 2011, 38, 284-308.
22. Kelley, R.K.; Van Bebber, S.L.; Phillips, K.A.; Venook, A.P. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J. Natl. Compr. Canc. Netw. 2011, 9, 13-25.
23. Amado, R.G.; Wolf, M.; Peeters, M.; van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S.D.; Chang, D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626-1634.
24. Jimeno, A.; Messersmith, W.A.; Hirsch, F.R.; Franklin, W.A.; Eckhardt, S.G. KRS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 2009, 27, 1130-1136.
25. Lievre, A.; Bachet, J.B.; Boige, V.; Cayre, A.; Le Corre, D.; Buc, E.; Ychou, M.; Bouché, O.; Landi, B.; Louvet, C.; André, T.; et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26, 374-379.
26. Sarasqueta, F.; Lijnshoten, G.; Lemmens, V.E.; Rutten, H.J.; van den Brule, A.J. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol. Diagn. Ther. 2011, 15, 277-283.
27. Castillo-Fernandez, O.; Santibanez, M.; Bauza, A.; Calderillo, G.; Castro, C.; Herrera, R.; Serrano, A.; Arrieta, O.; Herrera, L.A. Methylenetetrahydrofolatereductase polymorphism (677 C-T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch. Med. Res. 2010, 41, 430-433.
28. Boni, V.; Zarate, R.; Villa, J.C.; Bandrés, E.; Gomez, M.A.; Maiello, E.; Garcia-Foncillas, J.; Aranda, E. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics 2011, 11, 429-436.
29. Salgia R.; Hensing, T.; Campbell, N.; Salama, A.K.; Maitland, M.; Hoffman, P.; Villaflor, V.; Vokes, E.E. Personalized treatment of lung cancer. Semin. Oncol. 2011, 38, 74-83.
30. Curran, M.P. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 2012, 72, 99-107.
31. Ou, S.H. Crizotinib: a novel and first-in-class multitargeting tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des. Devel. Ther. 2011, 5, 471-485.
32. Shaw, A.T.; Solomon, B.; Kenudson, M.M. Crizotinib and testing for ALK. J. Natl. Compr. Netw. 2011, 9, 1335-1345.
33. Chmielecki, J.; Pietanza, M.C.; Aftab, D.; Shen, R.; Zhao, Z.; Chen, X.; Hutchinson, K.; Viale, A.; Kris, M.G.; Stout, T.; Miller, V.; Rizvi, N.; Pao, W. EGRR-mutant lung adenocarcinomas treated first line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J. Thorac. Oncol. 2011, PMID:22173702, in press.
34. O'Byrne, K.J.; Gatzemeir, U.; Bondarenko, I.; Barrios, C.; Eschbach, C.; Martens, U.M.; Hotko, Y.; Kortsik, C.; Paz-Ares, L.; Pereira, J.R.; von Pawel, J.; et al. Molecular biomarkers in nonsmall cell lung cancer: a retrospective analysis of data from the phase III FLEX study. Lancet Oncol. 2011, 12, 795-805.
35. Nyberg, F.; Barratt, B.J.; Mushiroda, T.; Takahashi, A.; Jawaid, A.; Hada, S.; Umemura, T.; Fukuoka, M.; Nakata, K.; Ohe, Y.; Kato, H.; et al. Interstitial lung disease in gefitinib treated Japanese patients with non-small cell lung cancer: genome-wide analysis of genetic data. Pharmacogenomics 2011, 12, 965-977.
36. Yin, J.Y.; Han, L.F.; Huang, Q.; Xu, X.J.; Zhou, H.H.; Liu, Z.Q. ABCC1 polymorphism Arg723Gln (2168G-A) is associated with lung cancer susceptibility in a Chinese population. Clin. Exp. Pharmaco. Physiol. 2011, 38, 632-637.
37. Wu, J.Y.; Shih, J.Y.; Chen, K.Y.; Yang, C.H.; Yu, C.J.; Yang, P.C. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine 2011, 90, 159-167.
38. Osawa, K. SNPs in ERCC1 and drug response to cisplatin in non-small cell lung cancer patients. Pharmacogenomics 2011, 12, 445-447.
39. Sajid, S.; Mohile, S.G.; Szmulewitz, R.; Posadas, E.; Dale, W. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin. Oncol. 2011, 38, 309-325.
40. Audet-Walsh, E.; Bellemare, J.; Nadeau, G.; Lacombe, L.; Fradet, Y.; Fradet, V.; Huang, S.P.; Bao, B.Y.; Douville, P.; Girard, H.; Guillemette, C.; et al. SRD5A polymorphism and biochemical failure after radical prostatectomy. Eur. Urol. 2011, 60, 1226-1234.
41. Bachmann, H.S.; Heukamp, L.C.; Schmitz, K.J.; Hilburn, C.F.; Kahl, P.; Buettner, R.; Nückel, H.; Eisenhardt, A.; Rübben, H.; Schmid, K.W.; Siffert, W.; et al. Regulatory BCL2 promoter polymorphism (938 C-A) is associated with adverse outcome in patients with prostate carcinoma. Int. J. Cancer. 2011, 129, 2390-2399.
42. Odenike, O.; Thirman, M.J.; Artz, A.S.; Godley, L.A.; Larson, R.A.; Stock, W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia; are we there yet? Semin. Oncol. 2011, 38, 196-214.
43. Godley, L.A.; Cunningham, J.; Dolan, M.E.; Huang, R.S.; Gurbuxani, S.; McNerney, M.E.; Larson, R.A.; Leong, H.; Lussier, Y.; Onel, K.; et al. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin. Oncol. 2011, 38, 215-224.
44. Takahashi, N.; Miura, M.; Scott, S.A.; Kagaya, H.; Kameoka, Y.; Tagawa, H.; Saitoh, H.; Fujishima, N.; Yoshioka, T.; Hirokawa, M.; Sawada, K. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet. 2010, 55, 731-737.
45. Ramsdale, E.; van Besien, K.; Smith, S.M. Personalized treatment of lymphoma: promise and reality. Semin Oncol. 2011, 38, 225-235.
46. Nasr, R.; Guillemin, M.C.; Ferhi, O.; Soilihi, H.; Peres, L.; Berthier, C.; Rousselot, P.; Robledo-Sarmiento, M.; Lallemand-Breitenbach, V.; Gourmel, B.; et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 2008, 14, 1333-1342.
47. Barbany, G.; Hoglund, M.; Simonsson, B.; Swedish CML Group. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N. Eng. J. Med. 2002, 347, 539-540.
48. Rossi, D.; Rasi, S.; Di Rocco, A.; Fabbri, A.; Forconi, F.; Gloghini, A.; Bruscaggin, A.; Franceschetti, S.; Fangazio, M.; De Paoli, L.; et al. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood 2011, 117, 2405-2413.
49. Vagace, J.M.; Caceres-Marzal, C.; Jimenez, M.; Casado, M.S.; de Murillo, S.G.; Gervasini, G. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am. J. Hematol. 2011, 86, 98-101.
50. Solit, D.; Sawyers, C.L. Drug discovery: how melanomas bypass new therapy. Nature 2010, 468, 902-903.